Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Eomesodermin and T-bet mark developmentally distinct human natural killer cells
Amélie Collins, Nyanza Rothman, Kang Liu, Steven L. Reiner
Amélie Collins, Nyanza Rothman, Kang Liu, Steven L. Reiner
View: Text | PDF
Research Article Development Immunology

Eomesodermin and T-bet mark developmentally distinct human natural killer cells

  • Text
  • PDF
Abstract

Immaturity of the immune system of human fetuses and neonates is often invoked to explain their increased susceptibility to infection; however, the development of the fetal innate immune system in early life remains incompletely explored. We now show that the most mature NK cells found in adult (or postnatal) human circulation (CD94–CD16+) are absent during ontogeny. Human fetal NK cells were found to express the 2 signature T-box transcription factors essential for the development of all murine NK and NK-like cells, eomesodermin (Eomes) and T-bet. The single-cell pattern of Eomes and T-bet expression during ontogeny, however, revealed a stereotyped pattern of reciprocal dominance, with immature NK cells expressing higher amounts of Eomes and more mature NK cells marked by greater abundance of T-bet. We also observed a stereotyped pattern of tissue-specific NK cell maturation during human ontogeny, with fetal liver being more restrictive to NK cell maturity than fetal bone barrow, spleen, or lung. These results support the hypothesis that maturation of human NK cells has a discrete restriction until postnatal life, and provide a framework to better understand the increased susceptibility of fetuses and newborns to infection.

Authors

Amélie Collins, Nyanza Rothman, Kang Liu, Steven L. Reiner

×

Figure 4

Eomeshi cells are less mature than T-bethi cells based on killer immunoglobulin receptor (KIR) and NKG2A expression.

Options: View larger image (or click on image) Download as PowerPoint
Eomeshi cells are less mature than T-bethi cells based on killer immunog...
(A) Mean frequencies ± SEM of KIR expression (based on pan-KIR staining for KIR2DL1, KIR2DS1, KIR2DL2, KIR2DS2, KIR2DL3, KIR2DS3, KIR2DS4, and KIR2DS5) on lineage-negative (Linneg: depleted of T cells, B cells, DCs, monocytes, granulocytes, erythroid cells, and CD34+ precursor cells) CD161+ stage 4 and 5 Eomeshi (open circles) and T-bethi (closed circles) cells from indicated tissues. Fetal bone marrow (BM), n = 7; fetal liver, n = 8; fetal lung, n = 9; fetal spleen, n = 8; umbilical cord blood (UCB), n = 6; adult spleen, 5 independent measurements made on n = 2 specimens. (B) Median fluorescence intensity (MFI) ± SEM of NKG2A on KIR-negative and KIR-positive Eomeshi (open circles) and T-bethi (closed circles) stage 5a (CD94+CD16+) cells from indicated tissues. Fetal BM, n = 7; fetal liver, n = 8; fetal lung, n = 9; fetal spleen, n = 8; UCB, n = 2; adult spleen (Adult S.), 5 independent measurements made on n = 2 specimens. Significance determined using 2-way ANOVA with Bonferroni post-hoc tests. *P < 0.05, ***P < 0.001, ****P < 0.0001. ns, not significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts